BMY Shares Snap Six-Day Gain with Minor Decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 46 minutes ago
0mins
Source: seekingalpha
- Stock Decline: Bristol-Myers Squibb (BMY) saw a minor decline of 0.15% on Friday, closing at $59.46 after six consecutive days of gains, indicating short-term market volatility.
- Analyst Ratings: Seeking Alpha's Quant Rating gives BMY a Hold rating of 3.37, with an A+ for profitability but a D- for growth, reflecting market caution regarding its future growth prospects.
- Analyst Opinions: Among 29 analysts, 10 rated BMY as a Buy, 18 as Hold, and 1 as Strong Sell, indicating a divergence in market sentiment, particularly as the company faces a major patent cliff.
- Future Catalysts: Analyst Joseph Minton highlighted that BMY's robust pipeline and CAR-T optionality position it for potential re-rating opportunities in 2026, with forward P/E ratios possibly reaching 10-11x, showcasing long-term investment value.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to fall
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 59.550
Low
37.00
Averages
55.86
High
68.00
Current: 59.550
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development, and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Orencia (abatacept), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Breyanzi (lisocabtagene maraleucel), Opdualag (nivolumab and relatlimab-rmbw), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), Sotyktu (deucravacitinib), Krazati (adagrasib), and Cobenfy (xanomeline and trospium chloride). Its other growth products include Augtyro, Onureg, Inrebic, Nulojix, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bristol Myers Squibb Showcases New Drug Research Results
- Successful Clinical Trials: Bristol Myers Squibb presented late-breaking results from the Phase 3 SUCCESSOR-2 trial of mezigdomide at the 2026 ASCO Annual Meeting, demonstrating its efficacy in relapsed or refractory multiple myeloma patients, potentially introducing a new treatment option in this area.
- Diverse Drug Pipeline: The company will also showcase various candidates including pumitamig, iza-bren, iberdomide, and golcadomide, highlighting their potential across different tumor types, thereby reinforcing its leadership position in oncology therapeutics.
- Innovative Treatment Combinations: During the meeting, Bristol Myers Squibb will emphasize innovative treatment combinations across multiple tumor types, aiming to provide meaningful options for cancer patients and enhancing the company's competitive edge in a crowded market.
- Global Collaborative Research: Collaboration with BioNTech will present the first global data for a PD-1 or PD-(L)1 x VEGF bispecific immunomodulator in previously untreated non-small cell lung cancer, further expanding the company's research impact on a global scale.
See More
BMY Shares Snap Six-Day Gain with Minor Decline
- Stock Decline: Bristol-Myers Squibb (BMY) saw a minor decline of 0.15% on Friday, closing at $59.46 after six consecutive days of gains, indicating short-term market volatility.
- Analyst Ratings: Seeking Alpha's Quant Rating gives BMY a Hold rating of 3.37, with an A+ for profitability but a D- for growth, reflecting market caution regarding its future growth prospects.
- Analyst Opinions: Among 29 analysts, 10 rated BMY as a Buy, 18 as Hold, and 1 as Strong Sell, indicating a divergence in market sentiment, particularly as the company faces a major patent cliff.
- Future Catalysts: Analyst Joseph Minton highlighted that BMY's robust pipeline and CAR-T optionality position it for potential re-rating opportunities in 2026, with forward P/E ratios possibly reaching 10-11x, showcasing long-term investment value.
See More
Bristol Myers Squibb's Stock Lacks Confidence Despite Strong Fundamentals
- Valuation Advantage: Bristol Myers Squibb's stock trades at approximately 10 times forward earnings, making it the cheapest among its 11 peers in the S&P 500, reflecting low market confidence in its future growth prospects.
- Attractive Dividend Yield: With only 8% stock returns so far this year, the dividend yield has surpassed 4%, second only to Pfizer in the pharmaceutical sector, appealing to income-seeking investors.
- Rapid Growth of New Products: In Q1 2026, Bristol Myers Squibb generated $11.5 billion in revenue, a 3% year-over-year increase, with its growth portfolio rising 12%, demonstrating resilience against patent expiration risks.
- Cost Control Measures: The company anticipates achieving approximately $2 billion in annual cost savings by 2027 through restructuring and productivity initiatives, further enhancing its financial health and market competitiveness.
See More
Bristol Myers Squibb Valuation Low but Growth Prospects Positive
- Strong Revenue Outlook: Bristol Myers Squibb anticipates revenue of up to $47.5 billion in 2023, demonstrating robust competitiveness in the pharmaceutical market, although facing patent expiration pressures, it is expected to maintain stable revenue growth.
- Cost Control Initiatives: Management plans to save approximately $2 billion annually by 2027 through restructuring and productivity improvements, which will enhance the company's profitability and improve cash flow.
- Rapid New Drug Growth: The company's new product portfolio achieved a 12% growth in Q1 2026, reaching $6.2 billion, with Breyanzi and Camzyos revenues increasing by 56% and 97% respectively, showcasing success in innovative drug development.
- Attractive Dividend Yield: Despite lackluster stock performance, Bristol Myers Squibb's dividend yield has surpassed 4%, ranking second in the pharmaceutical sector, attracting income-seeking investors and reflecting market caution regarding its future growth.
See More
BioArctic AB Reports Strong Earnings, Positive Outlook for Leqembi Sales
- Strong Financial Performance: BioArctic AB (BRCTF) reported over EUR 500 million in sales through its partner ACI for the fiscal year, indicating significant market potential in Alzheimer's treatment, with Leqembi sales expected to exceed USD 900 million in 2026, further solidifying its market position.
- Increased R&D Investment: The company anticipates a 40% to 60% rise in R&D spending compared to last year, primarily directed towards programs nearing IND-enabling stages, particularly the Ixidabumab project related to Parkinson's disease, which will enhance future product development and market competitiveness.
- Market Access Challenges: Despite facing challenges in market access for Leqembi in Sweden due to conservative health economic modeling assumptions, the company is actively exploring alternative pathways to ensure patient access, demonstrating its strong commitment to the market.
- Robust Financial Position: BioArctic AB currently holds over 2 billion Swedish crowns in cash reserves, which not only secures ongoing investments in projects but also lays the groundwork for potential dividend payments in the future, thereby boosting investor confidence.
See More
Bloomsbury Publishing Reports 7% Profit Increase and Dividend Boost
- Significant Profit Growth: Bloomsbury Publishing PLC reported a 7% increase in profits to £44.9 million, supporting a 5% dividend increase, demonstrating the company's resilience through diversified revenue streams, particularly in consumer and academic publishing.
- Doubling Academic Revenue: The academic and professional division generated £108 million in revenue with profits doubling to £25 million, indicating strong growth driven by digital sales, particularly in the expanding Asian market, which positions the company for further expansion.
- AI Licensing Agreement Potential: The partnership with Google for AI licensing is expected to enhance operational efficiency, although challenges exist in the AI market; the high-quality academic content will support future AI model training, strengthening the company's competitive edge.
- Optimistic Book Release Outlook: Pre-orders for upcoming releases from bestselling author Sarah J. Maas are extraordinarily high, reflecting robust market demand, which is anticipated to drive record profits in the coming year, further solidifying Bloomsbury's position in the publishing industry.
See More
Bristol Myers Squibb Showcases New Drug Research Results
- Successful Clinical Trials: Bristol Myers Squibb presented late-breaking results from the Phase 3 SUCCESSOR-2 trial of mezigdomide at the 2026 ASCO Annual Meeting, demonstrating its efficacy in relapsed or refractory multiple myeloma patients, potentially introducing a new treatment option in this area.
- Diverse Drug Pipeline: The company will also showcase various candidates including pumitamig, iza-bren, iberdomide, and golcadomide, highlighting their potential across different tumor types, thereby reinforcing its leadership position in oncology therapeutics.
- Innovative Treatment Combinations: During the meeting, Bristol Myers Squibb will emphasize innovative treatment combinations across multiple tumor types, aiming to provide meaningful options for cancer patients and enhancing the company's competitive edge in a crowded market.
- Global Collaborative Research: Collaboration with BioNTech will present the first global data for a PD-1 or PD-(L)1 x VEGF bispecific immunomodulator in previously untreated non-small cell lung cancer, further expanding the company's research impact on a global scale.
See More
BMY Shares Snap Six-Day Gain with Minor Decline
- Stock Decline: Bristol-Myers Squibb (BMY) saw a minor decline of 0.15% on Friday, closing at $59.46 after six consecutive days of gains, indicating short-term market volatility.
- Analyst Ratings: Seeking Alpha's Quant Rating gives BMY a Hold rating of 3.37, with an A+ for profitability but a D- for growth, reflecting market caution regarding its future growth prospects.
- Analyst Opinions: Among 29 analysts, 10 rated BMY as a Buy, 18 as Hold, and 1 as Strong Sell, indicating a divergence in market sentiment, particularly as the company faces a major patent cliff.
- Future Catalysts: Analyst Joseph Minton highlighted that BMY's robust pipeline and CAR-T optionality position it for potential re-rating opportunities in 2026, with forward P/E ratios possibly reaching 10-11x, showcasing long-term investment value.
See More
Bristol Myers Squibb's Stock Lacks Confidence Despite Strong Fundamentals
- Valuation Advantage: Bristol Myers Squibb's stock trades at approximately 10 times forward earnings, making it the cheapest among its 11 peers in the S&P 500, reflecting low market confidence in its future growth prospects.
- Attractive Dividend Yield: With only 8% stock returns so far this year, the dividend yield has surpassed 4%, second only to Pfizer in the pharmaceutical sector, appealing to income-seeking investors.
- Rapid Growth of New Products: In Q1 2026, Bristol Myers Squibb generated $11.5 billion in revenue, a 3% year-over-year increase, with its growth portfolio rising 12%, demonstrating resilience against patent expiration risks.
- Cost Control Measures: The company anticipates achieving approximately $2 billion in annual cost savings by 2027 through restructuring and productivity initiatives, further enhancing its financial health and market competitiveness.
See More
Bristol Myers Squibb Valuation Low but Growth Prospects Positive
- Strong Revenue Outlook: Bristol Myers Squibb anticipates revenue of up to $47.5 billion in 2023, demonstrating robust competitiveness in the pharmaceutical market, although facing patent expiration pressures, it is expected to maintain stable revenue growth.
- Cost Control Initiatives: Management plans to save approximately $2 billion annually by 2027 through restructuring and productivity improvements, which will enhance the company's profitability and improve cash flow.
- Rapid New Drug Growth: The company's new product portfolio achieved a 12% growth in Q1 2026, reaching $6.2 billion, with Breyanzi and Camzyos revenues increasing by 56% and 97% respectively, showcasing success in innovative drug development.
- Attractive Dividend Yield: Despite lackluster stock performance, Bristol Myers Squibb's dividend yield has surpassed 4%, ranking second in the pharmaceutical sector, attracting income-seeking investors and reflecting market caution regarding its future growth.
See More
BioArctic AB Reports Strong Earnings, Positive Outlook for Leqembi Sales
- Strong Financial Performance: BioArctic AB (BRCTF) reported over EUR 500 million in sales through its partner ACI for the fiscal year, indicating significant market potential in Alzheimer's treatment, with Leqembi sales expected to exceed USD 900 million in 2026, further solidifying its market position.
- Increased R&D Investment: The company anticipates a 40% to 60% rise in R&D spending compared to last year, primarily directed towards programs nearing IND-enabling stages, particularly the Ixidabumab project related to Parkinson's disease, which will enhance future product development and market competitiveness.
- Market Access Challenges: Despite facing challenges in market access for Leqembi in Sweden due to conservative health economic modeling assumptions, the company is actively exploring alternative pathways to ensure patient access, demonstrating its strong commitment to the market.
- Robust Financial Position: BioArctic AB currently holds over 2 billion Swedish crowns in cash reserves, which not only secures ongoing investments in projects but also lays the groundwork for potential dividend payments in the future, thereby boosting investor confidence.
See More
Bloomsbury Publishing Reports 7% Profit Increase and Dividend Boost
- Significant Profit Growth: Bloomsbury Publishing PLC reported a 7% increase in profits to £44.9 million, supporting a 5% dividend increase, demonstrating the company's resilience through diversified revenue streams, particularly in consumer and academic publishing.
- Doubling Academic Revenue: The academic and professional division generated £108 million in revenue with profits doubling to £25 million, indicating strong growth driven by digital sales, particularly in the expanding Asian market, which positions the company for further expansion.
- AI Licensing Agreement Potential: The partnership with Google for AI licensing is expected to enhance operational efficiency, although challenges exist in the AI market; the high-quality academic content will support future AI model training, strengthening the company's competitive edge.
- Optimistic Book Release Outlook: Pre-orders for upcoming releases from bestselling author Sarah J. Maas are extraordinarily high, reflecting robust market demand, which is anticipated to drive record profits in the coming year, further solidifying Bloomsbury's position in the publishing industry.
See More
